Anagrelide as a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 4, 1997, Pages 379-383

  Tefferi, Ayalew ^a   Silverstein, Murray N ^a   Petitt, Robert M ^a   Mesa, Ruben A ^a   Solberg Jr , Lawrence A ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anagrelide; Essential thrombocythemia; Mechanism of action; Side effects; Treatment

Indexed keywords

ANAGRELIDE;

CELL DIFFERENTIATION; DRUG EFFECT; DRUG POTENCY; FLUID RETENTION; HEADACHE; HEART ARRHYTHMIA; HUMAN; MEGAKARYOCYTE; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTHEMIA;

EID: 0030803837     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996112     Document Type: Review

References (54)

1. Tefferi A, MN Silverstein, HC Hoagland: Primary thrombocythemia. Semin Oncol 22:334-340, 1995.
2. Schafer AI: Essential thrombocythemia. Prog Hemostas Thromb 10:69-96, 1991.
3. Van Genderen PJ, JJ Michiels: Primary thrombocythemia: Diagnosis, clinical manifestations and management. Ann Hematol 67: 57-62, 1993.
4. Tefferi A, TC Ho, GJ Ahmann, JA Katzmann, PR Greipp: Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 97:374-378, 1994.
5. Stoll DB, P Peterson, R Exten, J Laszlo, AV Pisciotta, JT Ellis, P White, K Vaidya, M Bozdech, S Murphy: Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol 27:77-83, 1988.
6. Murphy S, H Iland, D Rosenthal, J Laszlo: Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 23:177-182, 1986.
7. Raskind WH, PJ Fialkow: The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 49:127-167, 1987.
8. Georgii A, T Buhr, G Buesche, A Kreft, H Choritz: Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22(Suppl 1):15-29, 1996.
9. Dickstein JI, JW Vardiman: Hematopathologic findings in the myeloproliferative disorders. Semin Oncol 22:355-373, 1995.
10. Chintagumpala MM, LL Kennedy, CP Steuber: Treatment of essential thrombocythemia with anagrelide. J Pediatr 127:495-498, 1995.
11. McIntyre KJ, HC Hoagland, MN Silverstein, RM Petitt: Essential thrombocythemia in young adults. Mayo Clin Proc 66:149-154, 1991.
12. Rozman C, M Giralt, E Feliu, D Rubio, MT Cortes: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991.
13. Fenaux P, M Simon, MT Caulier, JL Lai, J Goudemand, F Bauters: Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549-556, 1990.
14. Jabaily J, HJ Iland, J Laszlo, EW Massey, GB Faguet, J Briere, SA Landaw, AV Pisciotta: Neurologic manifestations of essential thrombocythemia. Ann Intern Med 99:513-518, 1983.
15. Michiels JJ, FW ten Kate, VD Vuzevski, J Abels: Histopathology of erythromelalgia in thrombocythaemia. Histopathology 8:669-678, 1984.
16. Michiels JJ, T van Joost: Erythromelalgia and thrombocythemia: A causal relation. J Am Acad Dermatol 22:107-111, 1990.
17. Beressi AH, A Tefferi, MN Silverstein, RM Petitt, HC Hoagland: Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 155:1217-1222, 1995.
18. Griesshammer M, H Heimpel, TC Pearson: Essential thrombocythemia and pregnancy. Leuk Lymphoma 22(Suppl 1):57-63, 1996.
19. Michiels JJ, J Abels, J Steketee, HH van Vliet, VD Vuzevski: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102:466-471, 1985.
20. Cortelazzo S, G Finazzi, M Ruggeri, O Vestri, M Galli, F Rodeghiero, T Barbui: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
21. Geller SA, E Shapiro: Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 77:353-356, 1982.
22. Shibata K, Y Shimamoto, K Suga, M Sano, M Matsuzaki, M Yamaguchi: Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - A brief review of recent literature. Acta Haematol 91:84-88, 1994.
23. van Genderen PJJ, IS Lucas, R van Strit, VD Vuzevski, FJ Prins, HDDM van Vliet, JJ Michiels: Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemostas 76:333-338, 1996.
24. Itin PH, RK Winkelmann: Cutaneous manifestations in patients with essential thrombocythemia. J Am Acad Dermatol 24:59-63, 1991.
25. Van Genderen PJ, JJ Michiels, R van Strik, J Lindemans, HH van Vliet: Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin. Thromb Haemostas 73: 210-214, 1995.
26. Michiels JJ, PJ Koudstaal, AH Mulder, HH van Vliet: Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110, 1993.
27. Van Genderen PJJ, PGH Mulder, M Waleboer, D Van de Moesdijk, JJ Michiels: Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin. Br J Haematol 97:179-184, 1997.
28. Cortelazzo S, P Viero, G Finazzi, A D'Emilio, F Rodeghiero, T Barbui: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990.
29. van Genderen PJ, JJ Michiels: Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23:73-77, 1994.
30. Michiels JJ, PJJ Van Genderen, J Lindemans, HHDM Van Vliet: Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma 22(Suppl 1):47-56, 1996.
31. Chistolini A, MG Mazzucconi, A Ferrari, G la Verde, G Ferrazza, F Dragoni, A Vitale, R Arcieri, F Mandelli: Essential thrombocythemia: A retrospective study on the clinical course of 100 patients. Haematologica 75:537-540, 1990.
32. Colombi M, F Radaelli, L Zocchi, AT Maiolo: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 67:2926-2930, 1991.
33. Randi ML, F Fabris, C Rossi, T Tison, E Barbone, A Girolami: Sex and age as prognostic factors in essential thrombocythemia. Haematologica 77:402-404, 1992.
34. Berk PD, LR Wasserman, SM Fruchtman, JD Goldberg: Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR. PD Berk, NI Berlin (eds): Polycythemia Vera and the Myeloproliferative Disorders. Saunders, Philadelphia, 1996, pp 166-194.
35. Landolfi R, C Patrono: Aspirin in polycythemia vera and essential thrombocythemia: Current facts and perspectives. Leuk Lymphoma 22(Suppl 1):83-86, 1996.
36. Barbui T, G Finazzi, E Dupuy, J-J Kiladjian, J Brière: Treatment strategies in essential thrombocythemia: A critical appraisal of various experiences in different centers. Leuk Lymphoma 22 (Suppl 1): 149-160, 1996.
37. Gaver RC, G Deeb, KA Pittman, RD Smyth: Disposition of anagrelide, an inhibitor of platelet aggregation. Clin Pharmacol Ther 29:381-386, 1981.
38. Spencer CM, RN Brogden: Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 47:809-822, 1994.
39. Gillespie E: Anagrelide: A potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem Pharmacol 37:2866-2868, 1988.
40. Courtwright WE, JO Buchanan, JS Fleming, R Taylor: The effect of multiple oral doses of anagrelide on ADP and collagen-induced platelet aggregation in normal male subjects. Clin Pharmacol Ther 33:220 (Abst), 1983.
41. Tang SS, MM Frojmovic: Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3′,5′-adenosine monophosphate phosphodiesterase. J Lab Clin Med 95:241-257, 1980.
42. Andes WA, RJ Noveck, JS Fleming: Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemostas 52:325-328, 1984.
43. Silverstein MN, ME Petrone, RM Petitt, MP Dement, RA Vukovich: The safety profile of anagrelide for treatment of thrombocythemia. Blood 88(Suppl 1):583 (Abst), 1996.
44. Silverstein MN, RM Petitt, LA Solberg Jr, JS Fleming, RC Knight, LP Schacter: Anagrelide: A new drug for treating thrombocytosis. N Engl J Med 318:1292-1294, 1988.
45. Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med 92:69-76, 1992.
46. Mazzucconi MG, V De Sanctis, A Chistolini, F Dragoni, F Mandelli: Therapy with anagrelide in patients affected by essential thrombocythemia: Preliminary results. Haematologica 77:315-317, 1992.
47. Balduini CL, G Bertolino, P Noris, E Ascari: Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 77:40-43, 1992.
48. Solberg LA Jr, KJ Oles, J Tarach, MN Silverstein, RM Petitt, L Schacter, J Fleming. The effects of anagrelide on human megakaryocytopoiesis. Blood 74(Suppl 1):20 (Abst), 1989.
49. Mazur EM, AG Rosmarin, PA Sohl, JL Newton, A Narendran: Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 79:1931-1937, 1992.
50. Lengfelder E, M Griesshammer, R Hehlmann: Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22 (Suppl 1):135-142, 1996.
51. Pardini S, F Dore, M Murineddu, S Bontigli, M Longinotti, B Grigliotti, B Spano: Alpha 2b-interferon therapy and pregnancy - Report of a case of essential thrombocythemia. Am J Hematol 43:78-79 (Letter), 1993.
52. Petit JJ, M Callis, A Fernandez de Sevilla: Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha 2b. Am J Hematol 40:80 (Letter), 1992.
53. Thornley S, A Manoharan: Successful treatment of essential thrombocythemia with alpha Interferon during pregnancy. Eur J Haematol 52:63-64 (Letter), 1994.
54. Watson KV, N Key: Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors. Br J Haematol 83:198-203, 1993.